Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief
Drugs & Targets
Trending Stories
- Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed - As fire encroached, City of Hope prepared to evacuate its Duarte campus
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - NCCN publishes patient resource on genetic testing to guide patient decisionmaking
- After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency
- New colorectal cancer screening strategies must advance the standard of care